China Medical System’s Innovative Oral Drug for Vitiligo, Povorcitinib Enrolls First Patient in China Phase III Clinical Trial

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”, 867.HK/8A8.SG) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited), has enrolled the first patient in the China Phase III clinical trial of its innovative oral JAK1 inhibitor Povorcitinib Phosphate Tablets (“povorcitinib” or the “Product”) for the treatment of vitiligo on 19 November 2026.   The trial is a multi-center, randomized,…

Read More

AI Labs leverages Google’s Gemini AI to bring market analysis into its Chatbot

Singapore – 19/11/2026 – (SeaPRwire) – AI Labs chatbot, AIV, combines crypto and equity market analysis with trading strategies and risk assessments, as it reports about 700,000 active users, daily trading volumes of US$50-100M a day, and total value locked (TVL) of $80-100M across its platform. AI Labs is using Google‘s Gemini artificial intelligence technology to power its AIV Chatbot, enabling users to explore cryptocurrency and equity markets through conversational analysis, trading scenarios and investment risk assessments. The chatbot goes beyond conventional price summaries by incorporating technical indicators, business fundamentals,…

Read More